Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Study of N-803 Combined With the Broadly Neutralizing Antibodies VRC07-523LS and PGT121 Plus or Minus haNK Cells for Reduction of HIV Reservoirs

NCT04144335 is registered in ClinicalTrials.gov with University of Minnesota as lead sponsor.

NCT NCT04144335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04144335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Study of N-803 Combined With the Broadly Neutralizing Antibodies VRC07-523LS and PGT121 Plus or Minus haNK Cells for Reduction of HIV Reservoirs
Lead sponsor
University of Minnesota
Phase
Phase 1/2
Overall status
Withdrawn
Start date
January 1, 2020
Completion date
December 31, 2020
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

aids, aids and infections, aids/hiv problem, hiv, hiv infections, hiv/aids